This review outlines current issues of the pharmacovigilance (PV) system in the Russian Federation, namely the present state of regulatory aspects, regulatory requirements in both Russia and the Eurasian Economic Union, and review of causes of under-reporting of adverse drug reactions. Specific attention will be focused on how the system is designed to monitor drug safety functions, reporting and accountability of pharmaceutical products, their manufacturers and medical staff, the role played by regional centers for drug-safety monitoring, and insufficient understanding of the part taken by patients in the system of PV. The prospects of the Russian PV system and its harmonization with global practice will also be discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2017.1336082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Pulmonary Fibrosis: National Database Analysis.
Biomedicines
November 2024
Pharmacovigilance Center, Information and Methodological Center for Expert Evaluation, Record and Analysis of Circulation of Medical Products Under the Federal Service for Surveillance in Healthcare, 4-1 Slavyanskaya Square, 109074 Moscow, Russia.
Background/objectives: Pulmonary fibrosis (PF) results in a progressive decline of lung function due to scarring. Drugs are among the most common causes of PF. The objective of our study was to reveal the structure of drugs involved in PF development.
View Article and Find Full Text PDF[Possibilities of effective interaction in the system pharmacovigilance at registration of medicinal undesirable reactions at patients of the senior age groups.].
Adv Gerontol
June 2024
Irkutsk State Medical Academy for Post-Graduate Education - Russian Medical Academy of Continuous Professional Education, 100 Ujybileynyi mkr., Irkutsk 664049, Russian Federation, e-mail:
In recent years, complications of drug therapy are an important medical problem. Data on adverse drug reactions (ADR) in patients of older age groups were analyzed. The object of the study was notification cards for unwanted reactions received from medical organizations of the Irkutsk region for period 2009-2020 years.
View Article and Find Full Text PDFStevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Analysis of the Russian Database of Spontaneous Reports.
Pharmaceuticals (Basel)
May 2024
Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia.
Article Synopsis
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe skin reactions to medications, and analyzing a national database provides valuable insights into their occurrence.
- A study was conducted using reports from the Russian National Pharmacovigilance database between April 2019 and December 2023, focusing on demographic data and the drugs implicated in SJS and TEN cases.
- Out of 170 reports, 32.9% were SJS, 67.1% were TEN, with a notable number of cases in both pediatric and elderly populations; the most common drugs linked to these conditions included lamotrigine, ibuprofen, and ceftriaxone.
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
Rheumatology (Oxford)
September 2024
Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Objective: To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA).
Methods: Patients with pJIA or sJIA from two open-label, 52-week phase 1b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight-based dosing regimens until commercial availability or up to 5 years. Pharmacokinetics, pharmacodynamics, and efficacy were assessed for up to 3 years, and safety for up to 5 years in the LTE.
Drug-Induced Anaphylaxis: National Database Analysis.
Pharmaceuticals (Basel)
January 2024
Pharmacovigilance Center, Information and Methodological Center for Expert Evaluation, Record and Analysis of Circulation of Medical Products under the Federal Service for Surveillance in Healthcare, 4-1 Slavyanskaya Square, 109074 Moscow, Russia.
(1) Background: National health system databases represent an important source of information about the epidemiology of adverse drug reactions including drug-induced allergy and anaphylaxis. Analysis of such databases may enhance the knowledge of healthcare professionals regarding the problem of drug-induced anaphylaxis. (2) Methods: A retrospective descriptive analysis was carried out of spontaneous reports (SRs) with data on drug-induced anaphylaxis (SRsAs) extracted from the Russian National Pharmacovigilance database (analyzed period 2 April 2019-21 June 2023).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!